Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in Healthcare

Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version

Glenmark also denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.

Read More

EU In Talks With Moderna, BioNtech, CureVac To Secure Possible COVID Vaccines

The talks follow a deal reached in June by four EU member states with AstraZeneca for the upfront purchase of 400 million doses of its potential COVID-19 vaccine, in principle available to all 27 EU nations.

Read More

Infectious Disease Specialists Ask US Govt To Ensure Remdesivir Supply

"We urge the administration to fully leverage all authorities including the Defense Production Act and other tools to ensure adequate supplies of remdesivir," the IDSA said.

Read More

India Approves Human Trials For Second COVID-19 Vaccine Candidate

India's approval for Zydus comes days after privately held Bharat Biotech got a similar green light for human studies for its vaccine candidate.

Read More

Wall Street Shifts Bets To Big Pharma As COVID-19 Vaccine Race Progresses

Companies including Pfizer and Johnson & Johnson have said they each aim to produce as many as 1 billion doses by the end of 2021.

Read More

Covid-19 Vaccine Status: Here's All You Need To Know

Here is the latest update on COVID-19 vaccines from different pharmaceutical companies

Read More

BioNTech And Pfizer's COVID-19 Vaccine Shows Potential In Human Trial

The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.

Read More

Oxford COVID-19 Vaccine Developers Encouraged By Immune Response But Cautious On Timeframe

"We're very happy that we're seeing the right sort of immune response that will give protection, and not the wrong sort," Gilbert said.

Read More

Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations

Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees ($71.54).

Read More

Bharat Biotech Announces India's First COVID-19 Vaccine Candidate 'COVAXIN' With DCGI Approval For Human Clinical Trials

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Read More

Temasek-Led Investor Group In $250 Million Vaccine Bet On Biontech

The investors are in for an early reckoning because BioNTech has said it expects first clinical data on its COVID-19 vaccine development programme known as BNT162 this month or in July.

Read More

CanSino's COVID-19 Vaccine Candidate Approved For Military Use In China

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year,

Read More

Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal

Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Read More

Carlyle Group To Buy 20% Stake In Piramal Pharma For Over Rs 3,700 Cr

The capital raise will accelerate Piramal Pharma's organic and inorganic growth plans,

Read More

Vaccine Makers Face Biggest Medical Manufacturing Feat In History

J&J has partnered with the U.S. government on a $1 billion investment to speed development and production of its vaccine, even before it's proven to work.

Read More